Literature DB >> 22732251

Mutation of the translation initiation codon in FGA causes congenital afibrinogenemia.

Yordanka Tirefort1, Olivat Rakoto Alson, Philippe de Moerloose, Marguerite Neerman-Arbez.   

Abstract

Congenital afibrinogenemia is characterized by the complete absence of fibrinogen, the precursor of the major protein constituent of the blood clot, fibrin. Extensive allelic heterogeneity has been found for this disorder and more than 40 mutations, the majority in FGA, have been identified in homozygosity or in compound heterozygosity. However, the continuous genetic analysis of additional patients still allows the identification of novel mutations and thus the greater understanding of fibrinogen structure and function. Here we report the identification of a novel missense mutation in FGA exon 1 affecting the translation initiation codon: c.1 A>T (ATG>TTG) M1L, identified in a young boy from Madagascar in compound heterozygosity with a second mutation in FGA exon 4: c.385 C>T (CGA>TGA) R129X. The patient suffered from occasional severe arthralgias (shoulder, knee) most likely caused by intra-articular bleeding with subsequent inflammation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22732251     DOI: 10.1097/MBC.0b013e328355a76e

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  2 in total

Review 1.  Human Fibrinogen: Molecular and Genetic Aspects of Congenital Disorders.

Authors:  Giovanni Luca Tiscia; Maurizio Margaglione
Journal:  Int J Mol Sci       Date:  2018-05-29       Impact factor: 5.923

2.  Identification and characterization of novel mutations implicated in congenital fibrinogen disorders.

Authors:  Natalie Smith; Larissa Bornikova; Leila Noetzli; Hugo Guglielmone; Salvador Minoldo; Donald S Backos; Linda Jacobson; Courtney D Thornburg; Miguel Escobar; Tara C White-Adams; Alisa S Wolberg; Marilyn Manco-Johnson; Jorge Di Paola
Journal:  Res Pract Thromb Haemost       Date:  2018-07-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.